Tarsus Pharmaceuticals

Company snapshot

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator program

• 1 approved product(s) across US/EU regulatory metadata.
• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Tarsus Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Tarsus Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   TP-05 (lotilaner oral), fasted group — Phase 1

2. Jun 8, 2026 Clinical update

   TP-05 (lotilaner oral capsules) — Phase 1

3. Jun 8, 2026 Clinical update

   TP-05 (lotilaner) Low Dose — Phase 2

4. Jun 8, 2026 Clinical update

   TP-03 (Lotilaner Ophthalmic Solution), 0.25% — Phase 1

5. Jun 8, 2026 Clinical update

   Low Dose TP-05 — Phase 2

View all clinical trial activity →

• What is Tarsus Pharmaceuticals?

  Tarsus Pharmaceuticals is a biotech organization headquartered in Irvine, USA. It trades on NYSE under ticker TARS. Primary therapeutic focus areas include Blepharitis, Meibomian Gland Dysfunction, Papulopustular Rosacea, Ocular Rosacea, Demodex Blepharitis. NovaPharmaNews links

• Is Tarsus Pharmaceuticals publicly traded?

  Yes. Tarsus Pharmaceuticals is listed with ticker TARS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Tarsus Pharmaceuticals develop or market?

  We link 10 drug profile(s) where Tarsus Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tarsus-pharmaceuticals#company-drugs.

• What are the latest developments for Tarsus Pharmaceuticals?

  In the last 12 months our linked public records show 14 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Tarsus Pharmaceuticals focus on?

  Tarsus Pharmaceuticals focuses on Blepharitis, Meibomian Gland Dysfunction, Papulopustular Rosacea based on our analysis of their pipeline programs and drug development activities.